Brought to you by 
Ember strikes alliance with Brigham & Women's Hospital
17 Oct 2012
Executive Summary
In its third deal with a tech transfer entity this year, metabolic disease-focused start-up Ember Therapeutics Inc. has received an exclusive option from Brigham and Women’s Hospital to two small molecule targets--retinaldehyde dehydrogenase 1 (Aldh1a1) and thioesterase superfamily member 1 (Them1)--that are associated with brown fat pathways and mechanisms.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ember strikes alliance with Brigham & Women's Hospital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice